Shares of Par Pharmaceutical Companies PRX surged more than 36% in pre-market trading after the company agreed to be bought by the investment firm TPG for $50 per share in cash.
The deal price represents a 37% premium over Par Pharmaceutical's closing price on Friday.
Par Pharmaceutical shares jumped 36.41% to $49.90 in pre-market trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in